Improving first-line decision-making and multidisciplinary approach in advanced urothelial carcinoma

Fechas
Fecha:
Del 15/09/26 al 30/11/26
Idioma
Idioma:
Inglés
Duración
Duración:
7,5 horas
Precio:
0,00 

Disponibilidad: Hay plazas

Overview

Why was this programme created?

The rapid evolution of therapeutic options for urothelial carcinoma makes continuous education based on the latest scientific evidence and multidisciplinary clinical expertise more essential than ever.

The management of locally advanced/metastatic urothelial carcinoma (la/mUC) and muscle-invasive bladder cancer (MIBC) has undergone a profound transformation in recent years. The introduction of novel therapeutic strategies together with the continuous evolution of scientific evidence has significantly increased the complexity of clinical decision-making.

This educational programme aims to provide a practical and evidence-based update on the latest advances, supporting healthcare professionals in integrating current evidence into everyday clinical practice through a multidisciplinary, patient-centred approach aligned with contemporary clinical recommendations.

Learning focused on clinical practice

Through virtual Journal Clubs, online learning modules and discussions of real-world clinical cases, the programme promotes critical appraisal of the scientific literature and its direct application to clinical decision-making in daily practice.

Learning Objectives

What will you achieve by the end of this programme?

This programme has been designed to strengthen clinical decision-making by enhancing knowledge, fostering critical appraisal of scientific evidence and encouraging multidisciplinary collaboration among healthcare professionals.

Overall learning objective

To enhance healthcare professionals’ knowledge, clinical competence and confidence in the management of urothelial carcinoma by facilitating the integration of the latest scientific evidence into routine clinical practice.

Update your knowledge
Gain an up-to-date understanding of the latest therapeutic advances and emerging scientific evidence in urothelial carcinoma.
Make better clinical decisions
Apply evidence-based clinical criteria to select the most appropriate therapeutic strategy for each patient.
Critically appraise the evidence
Interpret and critically evaluate clinical studies while assessing their applicability to everyday clinical practice.
Optimise clinical management
Recognise complex clinical scenarios, optimise treatment sequencing and improve the management of treatment-related toxicities.
Apply what you learn
Translate newly acquired knowledge into clinical practice through the analysis of real-world clinical cases and discussions with leading experts.

Target Audience

Who is this programme for?

This programme is designed for healthcare professionals involved in the treatment and follow-up of patients with urothelial carcinoma, promoting a multidisciplinary approach and evidence-based clinical practice.

Medical Oncology
Specialists involved in the systemic treatment of urothelial carcinoma and therapeutic decision-making.
Urology
Specialists responsible for the surgical management of urothelial carcinoma and multidisciplinary patient care.
Radiation Oncology
Specialists involved in radiotherapy and the multidisciplinary coordination of patient care.
Nursing
Nurses involved in patient follow-up, patient education and the management of treatment-related toxicities.
Pharmacy
Pharmacists involved in the optimisation, monitoring and safe use of oncology treatments.
In addition…

This programme is also intended for healthcare professionals from other medical and nursing specialties who wish to update their knowledge of advanced urothelial carcinoma management, develop their skills in the critical appraisal of scientific evidence, and strengthen its application in clinical practice.

Learning Methodology

Learning Methodology
How do you complete the programme?

The programme combines self-paced online learning modules with recordings of expert-led educational sessions delivered in Spanish and provided with English subtitles.

📚
1. Online learning modules
Complete the online learning modules and review the accompanying educational resources at your own pace.

🎥
2. Expert session recordings
Watch recordings of the expert educational sessions delivered in Spanish with professionally prepared English subtitles.

📝
3. Final assessment
Successfully complete the final assessment and submit the programme evaluation survey.

Learning resources

All online modules are available throughout the programme, allowing participants to progress at their own pace. The recordings of the educational sessions are provided in their original Spanish language with English subtitles to facilitate access for an international audience.

Programme

How is the programme structured?

The programme is organised into two complementary components: three live virtual Journal Clubs and three on-demand online learning modules.

Virtual Journal Clubs

Three live online sessions will be delivered on a monthly basis, focusing on the critical appraisal of recent scientific literature and its application to clinical practice.

Schedule: September, October and November 2026.
Duration: 90 minutes per session.

Webinar 1
Multidisciplinary decision-making in perioperative MIBC
Perioperative systemic treatment strategies, bladder preservation, management of cisplatin-ineligible patients and multidisciplinary decision-making.
Webinar 2
Management of treatment-related toxicities
Early recognition, management of toxicities associated with novel therapies, patient monitoring, patient education and multidisciplinary care coordination.
Webinar 3
First-line treatment in la/mUC: patient selection and treatment sequencing
Impact of novel therapies, treatment selection criteria, sequencing strategies and personalised treatment approaches.
On-demand online learning modules

To complement the live sessions, the programme includes three on-demand online learning modules aligned with the webinar content. Each module has an estimated duration of one hour and includes expert-led video lectures, summaries of key concepts, practical infographics and self-assessment activities.

Faculty

Faculty

Faculty

The programme is delivered by a multidisciplinary faculty with extensive expertise in medical education, medical oncology and genitourinary malignancies.

Programme Director
Prof. Clara Madrid Alejos

Senior Researcher at the Catalan Institute of Oncology (ICO) and Associate Professor at UVic-UCC. She has extensive experience in the design, coordination and evaluation of educational programmes for healthcare professionals.

Authors and Tutors
JG
Dr Javier Gavira Díaz
Medical Oncology

Specialist in genitourinary malignancies, with a particular interest in urothelial carcinoma, immunotherapy, precision oncology and clinical research.

LF
Dr Laia Fernández Mañas
Medical Oncology

Specialist in genitourinary malignancies, with a focus on optimising systemic therapies and promoting evidence-based clinical practice.

IO
Dr Irene Ortiz Rubio
Medical Oncology

Specialist in urothelial carcinoma, clinical research, personalised medicine and evidence-based therapeutic strategies.

Accreditation

How is this activity accredited?

This educational activity has been submitted for accreditation within the Spanish Continuing Professional Development (CPD) accreditation system for healthcare professionals.

Accreditation has been requested from the Catalan Council for Continuing Education of the Health Professions (CCFCPS) / Continuing Education Commission of the Spanish National Health System (CFC-SNS).

This is a Spanish national accreditation and does not correspond to European CME/CPD accreditation.

Important

The awarded credits are intended exclusively for licensed healthcare professionals in clinical practice. Healthcare professionals undertaking specialist training (medical residents) are not eligible for accreditation.

Scientific Independence

How is scientific independence ensured?

This educational activity is developed with full scientific, academic and editorial independence.

This educational programme is supported by an Independent Medical Education (IME) Grant from Astellas. The provision of this educational grant has not influenced, and will not influence, the programme design, content development, faculty selection, educational methodology, participant assessment or dissemination of the activity.

Scientific independence
The programme is planned and delivered with complete scientific, academic and editorial independence, in accordance with the principles governing independent medical education.

Carrito de compra
Scroll al inicio